Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 23 August, 2012 and appeared in  CardiovascularMedicationType 2 DiabetesIssue 640

Death Risk Drops by 50% for Diabetes Patients Using Statins

Type 2 diabetes patients on statin drugs have lower mortality risk....

Advertisement

In randomized clinical trials, involving 5,152 men and women from 66 to 96 years of age statin medications have been shown to reduce the risk of death in people with type 2 diabetes.

Vilmundur Gudnason, MD, PhD, of the University of Iceland, and colleagues wanted to see if statins had the same beneficial effect in observational studies on older people with type 2 diabetes.

They found that type 2 diabetes patients taking statin drugs had a 50 percent lower risk of dying from heart-related causes and a 53 percent lower risk of dying from all causes, compared to those not taking statins.

Among those without diabetes, statin use was associated with 16 percent lower risk of heart-related death and a 30 percent lower risk of death from all causes.

Diabetes patients who used statins had a similar risk of death as the general population without diabetes. In other words, statin use lowered the risk of death to normal levels, rather than the increased risk generally associated with diabetes.

According to the authors, this observational study adds to a body of evidence showing that statin use may be beneficial for people with type 2 diabetes.

The results urgently call for other population-based studies with comparable information to confirm the effect of statin use on death risk in individuals with type 2 diabetes.

BMJ Open August 2012

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 23 August, 2012 and appeared in  CardiovascularMedicationType 2 DiabetesIssue 640

Past five issues: Issue 744 | Diabetes Clinical Mastery Series Issue 203 | Issue 743 | Diabetes Clinical Mastery Series Issue 202 | SGLT-2 Inhibitors Special Edition August 2014 |

2014 Most Popular Articles:

Low-carb Diet Recommended for Type 1 and 2 Diabetes Patients
Posted August 01, 2014
New Combination of Diabetes Drugs Have Synergistic Effect
Posted August 08, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
New Encapsulated Beta-Cell Replacement Therapy for Type 1 Diabetes
Posted August 08, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
During Prolonged Low-Intensity Exercise, Caffeine Alters Blood Glucose
Posted August 15, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
SGLT2 Inhibitor Empagliflozin Wins FDA OK
Posted August 08, 2014
HbA1c Increases with Age
Posted August 01, 2014
Early Insulin Delays Diabetes But Are There Negative Consequences?
Posted August 15, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
When Afrezza is available, will you prescribe it immediately or wait until it has been on the market for a while?
CME/CE of the Week
William Tamborlane, MD, FAAP, FACE

Category: General Diabetes
Credits:
 .75
Search Articles On Diabetes In Control